KB407 utilizes a replication-defective HSV-1 vector to deliver full-length CFTR to the airway epithelium. The interim readout ...

LAWRENCEVILLE, N.J., Nov. 04, 2025 (GLOBE NEWSWIRE) -- IMUNON, Inc. (Nasdaq: IMNN), a clinical-stage company in Phase 3 development with its DNA-mediated immunotherapy, today announced that it will ...

The Company treated the first patient in the pivotal Phase 3 OVATION 3 Study in July 2025 and is working with trial investigators to expand clinical sites and accelerate enrollment. Four sites have ...

The Needle-Free Injection System Market represents a groundbreaking advancement in medical technology, offering an innovative ...

Bharat Biotech is venturing into advanced therapies by launching Nucelion Therapeutics, a subsidiary focused on cell and gene ...

The Society for Immunotherapy of Cancer (SITC) received an incredible number of abstract submissions in 2025, more than 1,300, including many clinical based Late-breaking Abstracts. SITC is proud to ...

INOVIO (NASDAQ: INO) announced that results from its Phase 1 proof-of-concept trial evaluating DNA-encoded monoclonal antibodies (DMAbs) for COVID-19 have been published in Nature Medicine. The ...

State Key Laboratory for Quality and Safety of Agro-Products, Key Laboratory of Biotechnology in Plant Protection of MARA, Zhejiang Key Laboratory of Green Plant Protection, Institute of Plant ...

This important study presents a thoughtful design and characterization of chimeric influenza hemagglutinin (HA) head domains combining elements of distinct receptor-binding sites. The results provide ...

The Society for Immunotherapy of Cancer (SITC) received over 1,300 abstract submissions in 2025, and has announced titles and authors for the accepted Late-breaking Abstracts (LBA). Late-breaking ...

President Trump has solidified the U.S.’s position as the world leader in artificial intelligence, attracting north of $1 trillion in AI investment, including $90 billion in groundbreaking AI and ...